#United States #Sarasota #Lakewood-Amedex #Bisphosphocin #Nu-3

Lakewood-Amedex Biotherapeutics: A Leader in Antimicrobial Solutions

Lakewood-Amedex Biotherapeutics Inc., a pioneering clinical-stage biotechnology firm, is gearing up to present at the much-anticipated BioFlorida Regional Event on October 1, 2025. This event will take place at The Roskamp Institute in Sarasota, Florida, where the company's Chief Executive Officer Kelvin Cooper, Ph.D., will take center stage.

Advancing Antimicrobial Excellence

The company's latest innovations revolve around a novel class of antimicrobial compounds known as the Bisphosphocin® class. These potent, fast-acting agents aim to tackle the pressing challenge of antimicrobial resistance (AMR) in healthcare. With the global health crisis attributed to AMR leading to nearly 5 million deaths annually, Lakewood-Amedex is strategically positioned to make a significant impact on treatment methodologies.

Dr. Cooper expresses excitement about the upcoming presentation, emphasizing the urgent need for advanced technologies in the battle against AMR: "I look forward to presenting to the BioFlorida community and discussing the critical need to develop improved technologies to address the growing threat of antimicrobial resistance."

The Lead Candidate: Nu-3

Central to Lakewood-Amedex’s research is their lead candidate, Nu-3, a topical gel specifically designed for treating infected diabetic foot ulcers (iDFU). This product is undergoing a Phase 2 clinical trial, an essential step towards establishing its effectiveness and safety in managing infections that commonly affect people with diabetes, a condition that sees approximately 13 million individuals in the U.S. facing diabetic foot ulcers, with 50% encountering infections during their lifetime.

The unique mechanism of action of Nu-3 allows it to disrupt microbial membranes, facilitating rapid bacterial cell death, thus demonstrating a compelling alternative to traditional antibiotic treatments. Dr. Cooper highlights the potential savings in both patient care and healthcare costs by utilizing this innovative technology: "We believe this technology has the potential to save millions of dollars in hospital stays and lengthy treatments typical of conventional standard of care antibiotics."

Broader Research Pipeline

Beyond Nu-3, Lakewood-Amedex is advancing a diverse range of early-stage pipeline compounds that leverage the Bisphosphocin platform. These candidates target various health concerns, including complicated urinary tract infections (cUTI) and pulmonary infections. As the healthcare landscape battles with AMR, the need for innovative solutions remains crucial, and Lakewood-Amedex is committed to leading the charge.

The BioFlorida Regional Event is an excellent opportunity for biotechnological advancements and networking among industry leaders, and Lakewood-Amedex Biotherapeutics will undoubtedly be a pivotal presence. This presentation will shed light on their groundbreaking research and its implications for future healthcare solutions.

Conclusion

In conclusion, Lakewood-Amedex Biotherapeutics is not only at the forefront of combating antimicrobial resistance but is also committed to innovation in biopharmaceuticals. With their focus on fast-acting, broad-spectrum antimicrobials, the company's efforts could herald a new era in infection management. Stay tuned for further developments post BioFlorida as Lakewood-Amedex continues to make strides in biotherapeutic innovations.

For more details on their efforts and current projects, visit Lakewood-Amedex's official website.